Tavneos (avacopan) / Amgen 
Welcome,         Profile    Billing    Logout  
 5 Diseases   7 Trials   7 Trials   708 News 


«123456789»
  • ||||||||||  Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
    ANCA-Associated Vasculitis Flare Presenting as Refractory Gastrointestinal Bleeding (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_4751;    
    A bipolar circum-active probe (BICAP) was done without success, followed by epinephrine, hemospray and endoclips placement achieving temporary hemostasis, but he continued to have melena...Rituximab infusion was started to achieve remission; dapsone was also given for its immunomodulator properties to prevent AAV relapse...AAV flare presenting as refractory GI bleed may be managed surgically along with using immunomodulators to achieve remission. Newer therapies like avacopan, a C5a receptor inhibitor that was found non-inferior to prednisone in clinical trials poses as an alternative treatment option.
  • ||||||||||  Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
    PR3 ANCA VASCULITIS PRESENTING AS NONRESOLVING PNEUMONIA FOLLOWING COVID-19 INFECTION (Convention Center Exhibit Hall: Poster Area 4) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_3016;    
    Early diagnosis and treatment are crucial to improving mortality in GPA. Younger patients may not fit the characteristic clinical picture and require a high degree of suspicion.
  • ||||||||||  Tavneos (avacopan) / Amgen
    Journal:  Avacopan's potential to decrease MPO-ANCA titres concurrent with ameliorated activity in ANCA-associated vasculitis. (Pubmed Central) -  Jul 8, 2024   
    The present case implies that avacopan-mediated inhibition of C5a may lead to a reduction in MPO-ANCA levels, thereby potentially ameliorating the pathophysiology of ANCA-associated vasculitis. Nevertheless, the impact of avacopan on MPO-ANCA production cannot be asserted solely based on this report; therefore, further examination is necessary through subgroup analysis using data from larger-scale studies.
  • ||||||||||  Tavneos (avacopan) / Amgen, Soliris (eculizumab) / AstraZeneca
    Review, Journal:  Updates on C3 Glomerulopathy in Kidney Transplantation: Pathogenesis and Treatment Options. (Pubmed Central) -  Jun 27, 2024   
    The most widely used treatments for the disease include corticosteroids and mycophenolate mofetil, which are already used chronically by kidney transplant recipients; thus, additional treatments for C3 glomerulopathy are required. Currently, several studies using anti-complement drugs (i.e., eculizumab, Ravalizumab, avacopan) for C3 glomerulopathy in kidney transplant patients are ongoing with encouraging results.
  • ||||||||||  Tavneos (avacopan) / Amgen
    Journal, Real-world evidence, Real-world:  Real-World Experience With Avacopan in Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. (Pubmed Central) -  Jun 20, 2024   
    After induction, the median (interquartile range [IQR]) time to start avacopan was 3.6 (2.1-7.7) weeks, and the median time to discontinue prednisone after starting avacopan was 5.6 (3.3-9.5) weeks...Of the patients, 20% stopped avacopan due to adverse events, with the most common being elevated serum aminotransferases (4.3%). A high rate of remission and an acceptable safety profile were observed with the use of avacopan in the treatment of AAV in this postmarketing analysis, including the populations excluded from the ADVOCATE trial.
  • ||||||||||  Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
    Journal:  A Refractory Case of Rapidly Progressive Glomerulonephritis Due to Microscopic Polyangiitis. (Pubmed Central) -  Jun 17, 2024   
    In addition, when used in place of steroids, they reduce the morbidity associated with cumulative glucocorticoid toxicity. For patients with ANCA-associated vasculitis refractory to standard therapies, targeted immunomodulators such as avacopan should be considered as alternative or adjunct therapy.
  • ||||||||||  Tavneos (avacopan) / Amgen, Nucala (mepolizumab) / GSK, Rituxan (rituximab) / Roche
    Journal:  ANCA-associated vasculitis - Treatment Standard. (Pubmed Central) -  May 30, 2024   
    There has been an increased attention on minimising the adverse effects of treatment and of understanding the epidemiology of co-morbidities in AAV. This review will focus on recent evidence from clinical trials, especially with respect to glucocorticoids, avacopan, plasma exchange, rituximab and mepolizumab, and their interpretation in the 2022 management recommendations by the European League of Associations of Rheumatology (EULAR).
  • ||||||||||  Tavneos (avacopan) / Amgen
    DESIGN OF AVACOSTAR: A REAL-WORLD STUDY OF AVACOPAN IN ANCA-ASSOCIATED VASCULITIS (AAV) () -  May 29, 2024 - Abstract #EULAR2024EULAR_4270;    
    P
    Avacopan was approved for the treatment of adult patients with severe active GPA and MPA in combination with rituximab or cyclophosphamide by the European Commission in January 2022... The AVACOSTAR study will be the largest real world evidence study conducted to date that evaluates long-term safety of novel therapeutics in GPA/MPA and is expected to yield important insights on the use of avacopan in GPA/MPA in a real-world setting, including continuation beyond 12 months.
  • ||||||||||  Tavneos (avacopan) / Amgen
    AVACOPAN IN THE TREATMENT OF ANCA-ASSOCIATED VASCULITIS: MULTICENTER PROSPECTIVE REAL-LIFE STUDY ON EFFICACY, SAFETY, AND IMPACT ON QUALITY OF LIFE () -  May 29, 2024 - Abstract #EULAR2024EULAR_4267;    
    The AVACOSTAR study will be the largest real world evidence study conducted to date that evaluates long-term safety of novel therapeutics in GPA/MPA and is expected to yield important insights on the use of avacopan in GPA/MPA in a real-world setting, including continuation beyond 12 months. The addition of avacopan to AAV induction therapy allows for a significant reduction in CS in the early weeks of treatment, with a good safety profile and positively impacting the perception of patients' quality of life.
  • ||||||||||  Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
    AVACOPAN IN ANCA-ASSOCIATED VASCULITIS RECEIVED INTENSIFIED INDUCTION THERAPY WITH CYCLOPHOSPHAMIDE PLUS RITUXIMAB  () -  May 29, 2024 - Abstract #EULAR2024EULAR_4266;    
    The observational study suggests that combination therapy with RTX/CYC together with avacopan appears to be well promising in the selected AAV patient population. However, controlled prospective studies investigating treatment efficacy of the combination of RTX/CYC as well as avacopan have to be considered to confirm the results.
  • ||||||||||  Tavneos (avacopan) / Amgen
    Journal:  Antineutrophil cytoplasmic antibody-associated vasculitis. (Pubmed Central) -  May 24, 2024   
    Kidney involvement in AAV requires prompt diagnosis and initiation of immunosuppression to prevent irreversible nephron loss. Newer therapeutic targets are on the horizon and offer hope for personalized treatment strategies.
  • ||||||||||  Tavneos (avacopan) / Amgen
    AVACOPAN VERSUS PREDNISONE TAPER IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS AND EAR, NOSE, OR THROAT INVOLVEMENT (A1) -  Mar 29, 2024 - Abstract #EULAR2024EULAR_1398;    
    Findings from this post hoc subgroup analysis of ADVOCATE in patients with MPA/GPA and active ENT manifestations at baseline showed that avacopan was associated with faster resolution of ENT manifestations, higher rate of overall sustained remission, lower relapse rate, numerically lower GC-related toxicity, greater improvement in HRQoL from baseline, and similar safety vs a prednisone taper. These data indicate avacopan may be efficacious in patients with ENT involvement of GPA/MPA.
  • ||||||||||  Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
    A refractory case of rapidly progressive glomerulonephritis due to microscopic polyangiitis () -  Mar 23, 2024 - Abstract #NKFSCM2024NKF_SCM_546;    
    MPA is a major cause of AAV and portends a poor prognosis without aggressive immunosuppressive therapy, including glucocorticoids and either rituximab or cyclophosphamide for severe cases. For many patients, especially those showing poor response to initial therapy, avacopan may provide a safer and potentially more efficacious treatment for AAV.
  • ||||||||||  Tavneos (avacopan) / Amgen
    AVACOPAN IN MPO-ANCA VASCULITIS: WHEN CORTICOSTEROIDS CAN NOT BE THE LONG TERM ANSWER (TUE-084; Main Foyer) -  Mar 8, 2024 - Abstract #ISNWCN2024ISN_WCN_960;    
    Avacopan, as a C5aR antagonist that blocks the effects of C5a, may reduce AAV-induced lesions, and is a new strategy to reduce drug side effects including CCT toxicity. Due to its incidence in older patients, these tend to have more comorbidities that may be aggravated with the current therapies, namely CCT.Avacopan has been used as an alternative in maintaining MPO-ANCA vasculitis remission, particularly in patients with an increased risk of CCT toxicity as was the case of our patient with several cardiovascular risk factors, besides the vasculitis itself, which was successfully treated with this approach.
  • ||||||||||  Tavneos (avacopan) / Amgen
    Enrollment open:  A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis (clinicaltrials.gov) -  Feb 25, 2024   
    P4,  N=300, Recruiting, 
    Due to its incidence in older patients, these tend to have more comorbidities that may be aggravated with the current therapies, namely CCT.Avacopan has been used as an alternative in maintaining MPO-ANCA vasculitis remission, particularly in patients with an increased risk of CCT toxicity as was the case of our patient with several cardiovascular risk factors, besides the vasculitis itself, which was successfully treated with this approach. Not yet recruiting --> Recruiting
  • ||||||||||  Tavneos (avacopan) / Amgen
    Avacopan for Treatment of MPO-ANCA Associated Vasculitis Presenting as Diffuse Alveolar Hemorrhage and Glomerulonephritis (San Diego Convention Center, Area G (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6122;    
    Two recent trials have demonstrated reduced-dose glucocorticoid regimens were noninferior to a high-dose glucocorticoid regimens when added to rituximab or cyclophosphamide for induction of remission in AAV (Furuta et al, Walsh et al for the PEXIVAS Investigators)...Findings were compatible with MPO- AAV, and she was treated with three daily 1g pulses of methylprednisolone followed by two daily doses of 60mg of prednisone...Avacopan is approved as an adjuvant for treatment of active severe AAV and its severe manifestations like DAH, where this agent should be considered standard of care for patients (Hellmich et al). In this patient, avacopan was safe, well tolerated, facilitated stabilization of renal and respiratory function, and allowed rapid glucocorticoid tapering.
  • ||||||||||  Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
    An Interesting Case of Drug-Induced Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis With Pulmonary and Renal Involvement (San Diego Convention Center, Area G (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_6120;    
    Exclusion of vasculitis associated with other etiologies like malignancy and infection is important in management. Our case was positive for ANCA with elevated MPO and PR3 titers, ANA with anti-chromatin antibodies and Anti-histone antibodies presented with pulmonary(BAH) renal syndrome(AKI), responded well to high dose solumedrol, Rituximab and Tavneosl, and stopping of hydralazine and allopurinol.
  • ||||||||||  Tavneos (avacopan) / Amgen, Rituxan (rituximab) / Roche
    ANCA Vasculitis Presenting With Diffuse Alveolar Hemorrhage (San Diego Convention Center, Area H (Hall H, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_5676;    
    Also, C5a receptor inhibitor avacopan was also utilized as an add-on therapy. This highlights the importance of recognizing the diagnosis and initiating the appropriate therapy in a timely manner.
  • ||||||||||  hydralazine hydrochloride / Generic mfg.
    Community Acquired Pneumonia or Hydralazine-Induced Vasculitis - A Clinical Dilemma (San Diego Convention Center, Area A (Hall A-B2, Ground Level)) -  Feb 20, 2024 - Abstract #ATS2024ATS_1586;    
    The patient was discharged home on prednisone with possible plans for initiating Avacopan...It is crucial to identify it and immediately stop hydralazine to prevent further damage. Depending on the severity of the vasculitis, patients may require treatment with immunosuppressive therapy especially if there is renal involvement.
  • ||||||||||  Tavneos (avacopan) / Kissei, Amgen, Otsuka
    Workshop 1A - Navigating the Future: Updates in ANCA Associated Vasculitis Management through Cases and Collaboration () -  Feb 8, 2024 - Abstract #CRAAHPA2024CRA_AHPA_19;    
    Topics covered will include the less is more paradigm shift in prednisone prescribing, adjuvant therapies in ANCA associated vasculitis (such as avacopan and plasmapheresis), how to select a maintenance agent, and how to decide on the duration of maintenance therapy. Attendees will also gain insight from the nephrology perspective so that they have the skills to collaborate with nephrology on these complex patients.CanMEDS rolesMedical ExpertCollaboratorHealth AdvocateScholarProfessional
  • ||||||||||  Tavneos (avacopan) / Kissei, Amgen, Otsuka
    Journal:  Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage. (Pubmed Central) -  Jan 25, 2024   
    We report the use of avacopan as a component of the treatment for pulmonary haemorrhage with hypoxia in AAV. Despite the life-threatening presentations all patients recovered, but attribution of the positive outcomes to avacopan is limited by the concomitant therapies and retrospective observational design.